

Special Issue

HIV/AIDS Prevention Formulation Design and Optimization and Its Pharmacokinetic- Pharmacodynamic Evaluation

Message from the Guest Editors

Daily oral re-exposure prophylaxis (PrEP) has been highly effective in preventing HIV acquisition when taken as prescribed, although inadequate adherence reduces efficacy and public health benefits. The development of new long-acting PrEP modalities that do not require frequent dosing is being actively pursued in order to overcome suboptimal drug adherence to daily oral PrEP. A bi-monthly injection of cabotegravir formulated as a nanoparticle suspension for intramuscular injection was the first long-acting regimen approved by the Food and Drug Administration (FDA) for PrEP in men and women. This Special Issue invites original research papers, communications or review articles that focus on the development of new long-acting drug formulations and controlled/extended release technologies for HIV PrEP, including (but not limited to) prodrug modifications, subdermal/subcutaneous implants, subcutaneous/intramuscular injectables, microarray patches, intravaginal rings, vaginal gels, inserts, and films. Articles studying pharmacokinetic/pharmacodynamic relationships in animal models are also considered as highly relevant for this Special Issue.

Guest Editors

Dr. José Gerardo García-Lerma

Laboratory Branch, Division of HIV Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329, USA

Dr. S. Rahima Benhabbour

1. Lampe Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

2. Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

Deadline for manuscript submissions

closed (31 August 2024)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/159725

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).